Drug |
Pharmacologic Class |
Indication |
More Information |
Dermatological Disorders | |||
Dupixent (dupilumab) | Interleukin-4 receptor alpha antagonist | Treatment of adult patients with prurigo nodularis. | Dupixent Drug Monograph |
Spevigo (spesolimab-sbzo) | Humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling | Treatment of generalized pustular psoriasis. | Spevigo Approved to Treat Generalized Pustular Psoriasis Flares |
Sotyktu (deucravacitinib) | Tyrosine kinase 2 inhibitor | Treatment of adults with moderate to severe plaque psoriasis who are candidates for a systemic therapy or phototherapy. | Sotyktu Drug Monograph |
Diagnostic Agents | |||
Elucirem and Vueway (gadopiclenol) | Macrocyclic gadolinium-based contrast agents | For use with magnetic resonance imaging in patients 2 years of age and older to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. | Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval |
Gastrohepatic Disorders | |||
Aponvie (aprepitant) | A substance P/neurokinin-1 receptor antagonist | For the prevention of postoperative nausea and vomiting in adults. | FDA Approves Aponvie for the Prevention of Postoperative Nausea, Vomiting |
Neurologic Disorders | |||
Relyvrio (sodium phenylbutyrate and taurursodiol) | Targets the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS | Treatment of amyotrophic lateral sclerosis in adults. | Relyvrio, a New Treatment Option for ALS, Gets FDA Approval |
Skysona (elivaldogene autotemcel) | Gene therapy designed to add functional copies of the ABCD1 cDNA into a patient’s own hematopoietic stem cells | To slow the progression of neurologic dysfunction in boys 4 to 17 years of age with early, active cerebral adrenoleukodystrophy. | Skysona Gets Accelerated Approval for Early, Active Cerebral Adrenoleukodystrophy |
Oncology | |||
Imfinzi (durvalumab) | Programmed death-ligand 1 blocking antibody | Treatment of adults with locally advanced or metastatic biliary tract cancer, in combination with gemcitabine and cisplatin. | Imfinzi Drug Monograph |
Lytgobi (futibatinib) | A selective and irreversible small molecule kinase inhibitor of FGFR 1, 2, 3, and 4 | Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements. | Lytgobi Gets Accelerated Approval for Intrahepatic Cholangiocarcinoma |
Pedmark (sodium thiosulfate injection) | Increases antioxidant glutathione levels and inhibits intracellular oxidative stress | To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, nonmetastatic solid tumors. | Pedmark Approved for Pediatric Cisplatin-Associated Ototoxicity |
Retevmo (selpercatinib) | Kinase inhibitor | Treatment of adults with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. | Retevmo Drug Monograph |
Ophthalmic Disorders | |||
Omlonti (omidenepag isopropyl) | Selective prostaglandin E2 (EP2) receptor agonist | To reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. | Omlonti Approved for Open-Angle Glaucoma, Ocular Hypertension |
Iheezo (chloroprocaine hydrochloride) | An ester anesthetic | Ocular surface anesthesia. | Iheezo Ophthalmic Gel Approved for Ocular Surface Anesthesia |
Urological Disorders | |||
Terlivaz (terlipressin) | Vasopressin analogue selective for V1 receptors | To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. | FDA Approves Terlivaz to Improve Kidney Function in Hepatorenal Syndrome |
Publish Date